{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:50Z","timestamp":1792783130395,"version":"4.5.0"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidade De S\u00e3o Paulo","id":[{"id":"https:\/\/ror.org\/036rp1748","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The MDM2\/p53\/p14ARF axis represents a central regulatory network controlling cell-cycle progression, genomic stability, and tumor suppression, and is frequently deregulated in human cancers. In many malignancies, particularly those retaining wild-type\n                    <jats:italic>TP53<\/jats:italic>\n                    , p53 activity is functionally suppressed through MDM2 overexpression or CDKN2A (p14ARF) loss, events that may be reversed in order to activate this pathway. This review explores the biological basis of the MDM2\/p53\/p14ARF axis and its relevance as a target for gene therapy and multimodal treatment strategies. While gene therapy for the restoration of p53 has been extensively explored, the use of genetic interventions for the inhibition of MDM2 or the restoration of p14ARF is underrepresented, though they have the potential to re-establish DNA damage responses, promote apoptosis, and enhance tumor sensitivity to chemotherapy and radiotherapy. In addition, p53 activation is now recognized as a contributor to immunogenic cell death and modulation of the tumor microenvironment. Laboratory and early clinical studies demonstrate that inhibition of MDM2 and restoration of p14ARF by gene transfer can integrate tumor cytotoxicity with immune activation. Although large-scale clinical validation remains limited, current evidence supports the MDM2\/p53\/p14ARF axis as a promising, context-dependent target within biomarker-driven combination therapies rather than a standalone approach.\n                  <\/jats:p>","DOI":"10.1007\/s11010-026-05742-4","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:39:50Z","timestamp":1789983590000},"page":"5125-5143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Opportunities in cancer gene therapy: inhibiting MDM2 and restoring p14ARF as a means to activate p53"],"prefix":"10.1007","volume":"481","author":[{"given":"Soraia Barbosa","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Laura Vieira","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Naomi","family":"Niitsuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Borel","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Lagonegro","family":"Amanatidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Luz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Egydio Oliveira","family":"Zambotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio Augusto","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan E.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"5742_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","volume":"21","author":"JS Brown","year":"2023","unstructured":"Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ (2023) Updating the definition of cancer. Mol Cancer Res 21:1142\u20131147. https:\/\/doi.org\/10.1158\/1541-7786.MCR-23-0411","journal-title":"Mol Cancer Res"},{"key":"5742_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","volume":"43","author":"GR Bhat","year":"2024","unstructured":"Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N, Albalawi IA, Masoodi T, Subbaraj GK, Jamal F, Singh M, Kumar R, Macha MA, Uddin S, Akil ASA, Haris M, Bhat AA (2024) Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev 43:197\u2013228. https:\/\/doi.org\/10.1007\/s10555-024-10172-z","journal-title":"Cancer Metastasis Rev"},{"key":"5742_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","volume":"9","author":"S Zhang","year":"2024","unstructured":"Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y, Lin D, Wu C (2024) Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther 9:149. https:\/\/doi.org\/10.1038\/s41392-024-01848-7","journal-title":"Signal Transduct Target Ther"},{"key":"5742_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"5742_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"key":"5742_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714\u201326. https:\/\/doi.org\/10.1038\/nrc3599","journal-title":"Nat Rev Cancer"},{"key":"5742_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69\u201380. https:\/\/doi.org\/10.1016\/j.cell.2010.02.027","journal-title":"Cell"},{"key":"5742_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","volume":"2","author":"LA Garraway","year":"2012","unstructured":"Garraway LA, Janne PA (2012) Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2:214\u2013226. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0012","journal-title":"Cancer Discov"},{"key":"5742_CR9","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW (2013) Cancer genome landscapes. Science 339:1546\u201358. https:\/\/doi.org\/10.1126\/science.1235122","journal-title":"Science"},{"key":"5742_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/sj.gt.3302238","volume":"11","author":"IA McNeish","year":"2004","unstructured":"McNeish IA, Bell SJ, Lemoine NR (2004) Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther 11:497\u2013503. https:\/\/doi.org\/10.1038\/sj.gt.3302238","journal-title":"Gene Ther"},{"key":"5742_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/humc.2018.112","volume":"30","author":"SW Shi","year":"2019","unstructured":"Shi SW, Li B, Dong Y, Ge Y, Qu X, Lu LG, Yuan YH, Li LJ, Li Y (2019) In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for malignant melanoma. Hum Gene Ther Clin Dev 30:7\u201318. https:\/\/doi.org\/10.1089\/humc.2018.112","journal-title":"Hum Gene Ther Clin Dev"},{"key":"5742_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.101155","volume":"11","author":"L Qi","year":"2024","unstructured":"Qi L, Li G, Li P, Wang H, Fang X, He T, Li J (2024) Twenty years of Gendicine(R) rAd-p53 cancer gene therapy: the first-in-class human cancer gene therapy in the era of personalized oncology. Genes Dis 11:101155. https:\/\/doi.org\/10.1016\/j.gendis.2023.101155","journal-title":"Genes Dis"},{"key":"5742_CR13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nature03485","volume":"434","author":"VG Gorgoulis","year":"2005","unstructured":"Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr., Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907\u201313. https:\/\/doi.org\/10.1038\/nature03485","journal-title":"Nature"},{"key":"5742_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nature03482","volume":"434","author":"J Bartkova","year":"2005","unstructured":"Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864\u2013870. https:\/\/doi.org\/10.1038\/nature03482","journal-title":"Nature"},{"key":"5742_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.celrep.2016.03.011","volume":"15","author":"CQX Yeo","year":"2016","unstructured":"Yeo CQX, Alexander I, Lin Z, Lim S, Aning OA, Kumar R, Sangthongpitag K, Pendharkar V, Ho VHB, Cheok CF (2016) p53 maintains genomic stability by preventing interference between transcription and replication. Cell Rep 15:132\u2013146. https:\/\/doi.org\/10.1016\/j.celrep.2016.03.011","journal-title":"Cell Rep"},{"key":"5742_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13:83\u201396. https:\/\/doi.org\/10.1038\/nrc3430","journal-title":"Nat Rev Cancer"},{"key":"5742_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188556","volume":"1876","author":"LJ Hernandez Borrero","year":"2021","unstructured":"Hernandez Borrero LJ, El-Deiry WS (2021) Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:188556. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188556","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"5742_CR18","first-page":"3","volume":"37","author":"T Hamzehloie","year":"2012","unstructured":"Hamzehloie T, Mojarrad M, Hasanzadeh Nazarabadi M, Shekouhi S (2012) The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy. Iran J Med Sci 37:3\u20138","journal-title":"Iran J Med Sci"},{"key":"5742_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y (2023) Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther 8:92. https:\/\/doi.org\/10.1038\/s41392-023-01347-1","journal-title":"Signal Transduct Target Ther"},{"key":"5742_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026054","author":"NT Pfister","year":"2017","unstructured":"Pfister NT, Prives C (2017) Transcriptional regulation by wild-type and cancer-related mutant forms of p53. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a026054","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5742_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s43018-024-00796-z","volume":"5","author":"G Efe","year":"2024","unstructured":"Efe G, Rustgi AK, Prives C (2024) p53 at the crossroads of tumor immunity. Nat Cancer 5:983\u2013995. https:\/\/doi.org\/10.1038\/s43018-024-00796-z","journal-title":"Nat Cancer"},{"key":"5742_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/387296a0","volume":"387","author":"Y Haupt","year":"1997","unstructured":"Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296\u2013299. https:\/\/doi.org\/10.1038\/387296a0","journal-title":"Nature"},{"key":"5742_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cell.2004.06.016","volume":"118","author":"DP Xirodimas","year":"2004","unstructured":"Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118:83\u201397. https:\/\/doi.org\/10.1016\/j.cell.2004.06.016","journal-title":"Cell"},{"key":"5742_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41418-024-01259-9","volume":"32","author":"A Janic","year":"2025","unstructured":"Janic A, Abad E, Amelio I (2025) Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control? Cell Death Differ 32:1\u20138. https:\/\/doi.org\/10.1038\/s41418-024-01259-9","journal-title":"Cell Death Differ"},{"key":"5742_CR25","doi-asserted-by":"publisher","unstructured":"Wolf ER, McAtarsney CP, Bredhold KE, Kline AM, Mayo LD (2018) Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK. Sci Signal 11. https:\/\/doi.org\/10.1126\/scisignal.aao4170","DOI":"10.1126\/scisignal.aao4170"},{"key":"5742_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/35074506","volume":"3","author":"S Llanos","year":"2001","unstructured":"Llanos S, Clark PA, Rowe J, Peters G (2001) Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 3:445\u201352. https:\/\/doi.org\/10.1038\/35074506","journal-title":"Nat Cell Biol"},{"key":"5742_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41392-020-0196-9","volume":"5","author":"L Chen","year":"2020","unstructured":"Chen L, Liu S, Tao Y (2020) Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther 5:90. https:\/\/doi.org\/10.1038\/s41392-020-0196-9","journal-title":"Signal Transduct Target Ther"},{"key":"5742_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-1-62703-236-0_4","volume":"962","author":"E Senturk","year":"2013","unstructured":"Senturk E, Manfredi JJ (2013) p53 and cell cycle effects after DNA damage. Methods Mol Biol 962:49\u201361. https:\/\/doi.org\/10.1007\/978-1-62703-236-0_4","journal-title":"Methods Mol Biol"},{"key":"5742_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-025-02051-7","author":"A Sadagopan","year":"2025","unstructured":"Sadagopan A, Carson M, Zamurs EJ, Garaffo N, Chang HJ, Schreiber SL, Meyerson M, Gibson WJ (2025) Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs. Nat Chem Biol. https:\/\/doi.org\/10.1038\/s41589-025-02051-7","journal-title":"Nat Chem Biol"},{"key":"5742_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41420-025-02366-3","volume":"11","author":"J Yang","year":"2025","unstructured":"Yang J, Zhou F, Luo X, Fang Y, Wang X, Liu X, Xiao R, Jiang D, Tang Y, Yang G, You L, Zhao Y (2025) Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies. Cell Death Discov 11:84. https:\/\/doi.org\/10.1038\/s41420-025-02366-3","journal-title":"Cell Death Discov"},{"key":"5742_CR31","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.237453","author":"J Blagih","year":"2020","unstructured":"Blagih J, Buck MD, Vousden KH (2020) P53, cancer and the immune response. J Cell Sci. https:\/\/doi.org\/10.1242\/jcs.237453","journal-title":"J Cell Sci"},{"key":"5742_CR32","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-24-3628","volume":"31","author":"Z Nian","year":"2025","unstructured":"Nian Z, Dou Y, Wei H (2025) p53: an immune ecosystem manipulator. Clin Cancer Res 31:5120\u20135127. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3628","journal-title":"Clin Cancer Res"},{"key":"5742_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1148389","volume":"10","author":"L Carlsen","year":"2023","unstructured":"Carlsen L, Zhang S, Tian X, De La Cruz A, George A, Arnoff TE, El-Deiry WS (2023) The role of p53 in anti-tumor immunity and response to immunotherapy. Front Mol Biosci 10:1148389. https:\/\/doi.org\/10.3389\/fmolb.2023.1148389","journal-title":"Front Mol Biosci"},{"key":"5742_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1517\/14712598.8.7.941","volume":"8","author":"S Assadian","year":"2008","unstructured":"Assadian S, Teodoro JG (2008) Regulation of collagen-derived antiangiogenic factors by p53. Expert Opin Biol Ther 8:941\u2013950. https:\/\/doi.org\/10.1517\/14712598.8.7.941","journal-title":"Expert Opin Biol Ther"},{"key":"5742_CR35","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1038\/s41388-020-1359-4","volume":"39","author":"ER Wolf","year":"2020","unstructured":"Wolf ER, Mabry AR, Damania B, Mayo LD (2020) Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors. Oncogene 39:5228\u20135239. https:\/\/doi.org\/10.1038\/s41388-020-1359-4","journal-title":"Oncogene"},{"key":"5742_CR36","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu Y, Su Z, Tavana O, Gu W (2024) Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell 42:946\u2013967. https:\/\/doi.org\/10.1016\/j.ccell.2024.04.009","journal-title":"Cancer Cell"},{"key":"5742_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217614","volume":"617","author":"HH Wu","year":"2025","unstructured":"Wu HH, Leng S, Eisenstat DD, Sergi C, Leng R (2025) Targeting p53 for immune modulation: exploring its functions in tumor immunity and inflammation. Cancer Lett 617:217614. https:\/\/doi.org\/10.1016\/j.canlet.2025.217614","journal-title":"Cancer Lett"},{"key":"5742_CR38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C (2020) Immune checkpoint signaling and cancer immunotherapy. Cell Res 30:660\u2013669. https:\/\/doi.org\/10.1038\/s41422-020-0343-4","journal-title":"Cell Res"},{"key":"5742_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.818744","volume":"10","author":"CP Kung","year":"2022","unstructured":"Kung CP, Weber JD (2022) It\u2019s getting complicated-a fresh look at p53-MDM2-ARF triangle in tumorigenesis and cancer therapy. Front Cell Dev Biol 10:818744. https:\/\/doi.org\/10.3389\/fcell.2022.818744","journal-title":"Front Cell Dev Biol"},{"key":"5742_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03356-8","volume":"24","author":"Y Yao","year":"2024","unstructured":"Yao Y, Zhang Q, Li Z, Zhang H (2024) MDM2: current research status and prospects of tumor treatment. Cancer Cell Int 24:170. https:\/\/doi.org\/10.1186\/s12935-024-03356-8","journal-title":"Cancer Cell Int"},{"key":"5742_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101279","volume":"11","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Zeng S, Dai X, Ding Y, Huang C, Ruan R, Xiong J, Tang X, Deng J (2024) MDM2 inhibitors in cancer immunotherapy: current status and perspective. Genes Dis 11:101279. https:\/\/doi.org\/10.1016\/j.gendis.2024.101279","journal-title":"Genes Dis"},{"key":"5742_CR42","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20240757","author":"IY Zhu","year":"2025","unstructured":"Zhu IY, Lloyd A, Critchley WR, Saikia Q, Jade D, Divan A, Zeqiraj E, Harrison MA, Brown CJ, Ponnambalam S (2025) Structure and function of MDM2 and MDM4 in health and disease. Biochem J. https:\/\/doi.org\/10.1042\/BCJ20240757","journal-title":"Biochem J"},{"key":"5742_CR43","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/sj.cdd.4402309","volume":"15","author":"K Linke","year":"2008","unstructured":"Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL (2008) Structure of the MDM2\/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 15:841\u2013848. https:\/\/doi.org\/10.1038\/sj.cdd.4402309","journal-title":"Cell Death Differ"},{"key":"5742_CR44","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1073\/pnas.1416656112","volume":"112","author":"CN Batuello","year":"2015","unstructured":"Batuello CN, Hauck PM, Gendron JM, Lehman JA, Mayo LD (2015) Src phosphorylation converts Mdm2 from a ubiquitinating to a neddylating E3 ligase. Proc Natl Acad Sci U S A 112:1749\u20131754. https:\/\/doi.org\/10.1073\/pnas.1416656112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5742_CR45","doi-asserted-by":"publisher","first-page":"104455","DOI":"10.18632\/oncotarget.22320","volume":"8","author":"PM Hauck","year":"2017","unstructured":"Hauck PM, Wolf ER, Olivos DJ 3rd, McAtarsney CP, Mayo LD (2017) The fate of murine double minute X (MdmX) is dictated by distinct signaling pathways through murine double minute 2 (Mdm2). Oncotarget 8:104455\u2013104466. https:\/\/doi.org\/10.18632\/oncotarget.22320","journal-title":"Oncotarget"},{"key":"5742_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1515\/bmc-2013-0027","volume":"5","author":"M Mendoza","year":"2014","unstructured":"Mendoza M, Mandani G, Momand J (2014) The MDM2 gene family. Biomol Concepts 5:9\u201319. https:\/\/doi.org\/10.1515\/bmc-2013-0027","journal-title":"Biomol Concepts"},{"key":"5742_CR47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ (2020) p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer 20:471\u2013480. https:\/\/doi.org\/10.1038\/s41568-020-0262-1","journal-title":"Nat Rev Cancer"},{"key":"5742_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/genes12091446","author":"S Vadivel Gnanasundram","year":"2021","unstructured":"Vadivel Gnanasundram S, Bonczek O, Wang L, Chen S, Fahraeus R (2021) P53 mRNA metabolism links with the DNA damage response. Genes (Basel). https:\/\/doi.org\/10.3390\/genes12091446","journal-title":"Genes (Basel)"},{"key":"5742_CR49","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1007\/s11033-023-08512-3","volume":"50","author":"A Zafar","year":"2023","unstructured":"Zafar A, Khan MJ, Naeem A (2023) MDM2- an indispensable player in tumorigenesis. Mol Biol Rep 50:6871\u20136883. https:\/\/doi.org\/10.1007\/s11033-023-08512-3","journal-title":"Mol Biol Rep"},{"key":"5742_CR50","doi-asserted-by":"publisher","first-page":"7681","DOI":"10.1038\/sj.onc.1202954","volume":"18","author":"DB Yap","year":"1999","unstructured":"Yap DB, Hsieh JK, Chan FS, Lu X (1999) mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18:7681\u20137689. https:\/\/doi.org\/10.1038\/sj.onc.1202954","journal-title":"Oncogene"},{"key":"5742_CR51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1172\/JCI39194","volume":"120","author":"S Araki","year":"2010","unstructured":"Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, Danielpour D, Pollok KE, Boothman DA, Mayo LD (2010) TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest 120:290\u2013302. https:\/\/doi.org\/10.1172\/JCI39194","journal-title":"J Clin Invest"},{"key":"5742_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026336","author":"JD Oliner","year":"2016","unstructured":"Oliner JD, Saiki AY, Caenepeel S (2016) The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a026336","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5742_CR53","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","volume":"76","author":"W Wang","year":"2024","unstructured":"Wang W, Albadari N, Du Y, Fowler JF, Sang HT, Xian W, McKeon F, Li W, Zhou J, Zhang R (2024) MDM2 inhibitors for cancer therapy: the past, present, and future. Pharmacol Rev 76:414\u2013453. https:\/\/doi.org\/10.1124\/pharmrev.123.001026","journal-title":"Pharmacol Rev"},{"key":"5742_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/biom11010086","author":"N Lagopati","year":"2021","unstructured":"Lagopati N, Belogiannis K, Angelopoulou A, Papaspyropoulos A, Gorgoulis V (2021) Non-canonical functions of the ARF tumor suppressor in development and tumorigenesis. Biomolecules. https:\/\/doi.org\/10.3390\/biom11010086","journal-title":"Biomolecules"},{"key":"5742_CR55","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s11010-020-03996-0","volume":"476","author":"R Vashi","year":"2021","unstructured":"Vashi R, Patel BM (2021) Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head! Mol Cell Biochem 476:1365\u20131375. https:\/\/doi.org\/10.1007\/s11010-020-03996-0","journal-title":"Mol Cell Biochem"},{"key":"5742_CR56","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.cell.2005.03.037","volume":"121","author":"D Chen","year":"2005","unstructured":"Chen D, Kon N, Li M, Zhang W, Qin J, Gu W (2005) ARF-BP1\/Mule is a critical mediator of the ARF tumor suppressor. Cell 121:1071\u20131083. https:\/\/doi.org\/10.1016\/j.cell.2005.03.037","journal-title":"Cell"},{"key":"5742_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nature02514","volume":"429","author":"D Dornan","year":"2004","unstructured":"Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O\u2019Rourke K, Koeppen H, Dixit VM (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429:86\u201392. https:\/\/doi.org\/10.1038\/nature02514","journal-title":"Nature"},{"key":"5742_CR58","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3109\/10428194.2012.684348","volume":"53","author":"EM Alexandrova","year":"2012","unstructured":"Alexandrova EM, Moll UM (2012) Role of p53 family members p73 and p63 in human hematological malignancies. Leuk Lymphoma 53:2116\u20132129. https:\/\/doi.org\/10.3109\/10428194.2012.684348","journal-title":"Leuk Lymphoma"},{"key":"5742_CR59","first-page":"5636","volume":"61","author":"SA Nicholson","year":"2001","unstructured":"Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD, Jett JR, Tazelaar HD, Trastek V, Pairolero PC, Corn PG, Herman JG, Liotta LA, Caporaso NE, Harris CC (2001) Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 61:5636\u20135643","journal-title":"Cancer Res"},{"key":"5742_CR60","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1016\/j.febslet.2011.06.015","volume":"585","author":"SV Khoronenkova","year":"2011","unstructured":"Khoronenkova SV, Dianov GL (2011) The emerging role of Mule and ARF in the regulation of base excision repair. FEBS Lett 585:2831\u20132835. https:\/\/doi.org\/10.1016\/j.febslet.2011.06.015","journal-title":"FEBS Lett"},{"key":"5742_CR61","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12929-018-0470-0","volume":"25","author":"SH Kao","year":"2018","unstructured":"Kao SH, Wu HT, Wu KJ (2018) Ubiquitination by HUWE1 in tumorigenesis and beyond. J Biomed Sci 25:67. https:\/\/doi.org\/10.1186\/s12929-018-0470-0","journal-title":"J Biomed Sci"},{"key":"5742_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112496","volume":"42","author":"JK Monda","year":"2023","unstructured":"Monda JK, Ge X, Hunkeler M, Donovan KA, Ma MW, Jin CY, Leonard M, Fischer ES, Bennett EJ (2023) HAPSTR1 localizes HUWE1 to the nucleus to limit stress signaling pathways. Cell Rep 42:112496. https:\/\/doi.org\/10.1016\/j.celrep.2023.112496","journal-title":"Cell Rep"},{"key":"5742_CR63","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2174\/092986707781058869","volume":"14","author":"AJ Saporita","year":"2007","unstructured":"Saporita AJ, Maggi LB Jr., Apicelli AJ, Weber JD (2007) Therapeutic targets in the ARF tumor suppressor pathway. Curr Med Chem 14:1815\u20131827. https:\/\/doi.org\/10.2174\/092986707781058869","journal-title":"Curr Med Chem"},{"key":"5742_CR64","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/febs.14373","volume":"285","author":"E Luchinat","year":"2018","unstructured":"Luchinat E, Chiarella S, Franceschini M, Di Matteo A, Brunori M, Banci L, Federici L (2018) Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf. FEBS J 285:832\u2013847. https:\/\/doi.org\/10.1111\/febs.14373","journal-title":"FEBS J"},{"key":"5742_CR65","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1038\/s41388-022-02318-6","volume":"41","author":"Y Liu","year":"2022","unstructured":"Liu Y, Luo Y, Yan S, Lian YF, Wu S, Xu M, Feng L, Zhang X, Li R, Zhang X, Feng QS, Zeng YX, Zhang H (2022) CRL2(KLHDC3) mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression. Oncogene 41:3104\u20133117. https:\/\/doi.org\/10.1038\/s41388-022-02318-6","journal-title":"Oncogene"},{"key":"5742_CR66","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026245","author":"S Wang","year":"2017","unstructured":"Wang S, Zhao Y, Aguilar A, Bernard D, Yang CY (2017) Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: progress and challenges. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a026245","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5742_CR67","doi-asserted-by":"publisher","first-page":"631","DOI":"10.4155\/fmc.15.13","volume":"7","author":"B Zhang","year":"2015","unstructured":"Zhang B, Golding BT, Hardcastle IR (2015) Small-molecule MDM2-p53 inhibitors: recent advances. Future Med Chem 7:631\u2013645. https:\/\/doi.org\/10.4155\/fmc.15.13","journal-title":"Future Med Chem"},{"key":"5742_CR68","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1021\/jm501092z","volume":"58","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Aguilar A, Bernard D, Wang S (2015) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem 58:1038\u20131052. https:\/\/doi.org\/10.1021\/jm501092z","journal-title":"J Med Chem"},{"key":"5742_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29225315","author":"Y Peng","year":"2024","unstructured":"Peng Y, Bai J, Li W, Su Z, Cheng X (2024) Advancements in p53-based anti-tumor gene therapy research. Molecules. https:\/\/doi.org\/10.3390\/molecules29225315","journal-title":"Molecules"},{"key":"5742_CR70","first-page":"1","volume-title":"Viruses as Therapeutic Agents for Cancer","author":"ALV Alves","year":"2026","unstructured":"Alves ALV, Niitsuma BN, Antunes F, Luz J, Barbosa M, Rodrigues OA, Oliveira S, Strauss BE (2026) Non-replicating adenoviral vectors for cancer gene therapy. In: Curiel DT (ed) Viruses as Therapeutic Agents for Cancer, vol Volume 171, edn. Elsevier, pp 1\u201334","edition":"edn"},{"key":"5742_CR71","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm0996-985","volume":"2","author":"JA Roth","year":"1996","unstructured":"Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985\u2013991. https:\/\/doi.org\/10.1038\/nm0996-985","journal-title":"Nat Med"},{"key":"5742_CR72","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/hum.1995.6.2-155","volume":"6","author":"WW Zhang","year":"1995","unstructured":"Zhang WW, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA (1995) Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum Gene Ther 6:155\u2013164. https:\/\/doi.org\/10.1089\/hum.1995.6.2-155","journal-title":"Hum Gene Ther"},{"key":"5742_CR73","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/hum.2017.218","volume":"29","author":"WW Zhang","year":"2018","unstructured":"Zhang WW, Li L, Li D, Liu J, Li X, Li W, Xu X, Zhang MJ, Chandler LA, Lin H, Hu A, Xu W, Lam DM (2018) The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther 29:160\u2013179. https:\/\/doi.org\/10.1089\/hum.2017.218","journal-title":"Hum Gene Ther"},{"key":"5742_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41368-021-00145-1","volume":"13","author":"Y Li","year":"2021","unstructured":"Li Y, Guo W, Li X, Zhang J, Sun M, Tang Z, Ran W, Yang K, Huang G, Li L (2021) Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers. Int J Oral Sci 13:38. https:\/\/doi.org\/10.1038\/s41368-021-00145-1","journal-title":"Int J Oral Sci"},{"key":"5742_CR75","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1349-7006.2006.00206.x","volume":"97","author":"H Shimada","year":"2006","unstructured":"Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S, Nabeya Y, Shuto K, Hayashi H, Tanizawa T, Nakatani Y, Nakasa H, Kitada M, Ochiai T (2006) Phase I\/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 97:554\u2013561. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00206.x","journal-title":"Cancer Sci"},{"key":"5742_CR76","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/sj.cgt.7700472","volume":"9","author":"RE Buller","year":"2002","unstructured":"Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M (2002) A phase I\/II trial of rAd\/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 9:553\u2013566. https:\/\/doi.org\/10.1038\/sj.cgt.7700472","journal-title":"Cancer Gene Ther"},{"key":"5742_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645745","volume":"11","author":"RE Sobol","year":"2021","unstructured":"Sobol RE, Menander KB, Chada S, Wiederhold D, Sellman B, Talbott M, Nemunaitis JJ (2021) Analysis of adenoviral p53 gene therapy clinical trials in recurrent head and neck squamous cell carcinoma. Front Oncol 11:645745. https:\/\/doi.org\/10.3389\/fonc.2021.645745","journal-title":"Front Oncol"},{"key":"5742_CR78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omto.2020.03.016","volume":"17","author":"T Koujima","year":"2020","unstructured":"Koujima T, Tazawa H, Ieda T, Araki H, Fushimi T, Shoji R, Kuroda S, Kikuchi S, Yoshida R, Umeda Y, Teraishi F, Urata Y, Mizuguchi H, Fujiwara T (2020) Oncolytic virus-mediated targeting of the ERK signaling pathway inhibits invasive propensity in human pancreatic cancer. Mol Ther Oncolytics 17:107\u2013117. https:\/\/doi.org\/10.1016\/j.omto.2020.03.016","journal-title":"Mol Ther Oncolytics"},{"key":"5742_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.omto.2022.09.003","volume":"27","author":"H Araki","year":"2022","unstructured":"Araki H, Tazawa H, Kanaya N, Kajiwara Y, Yamada M, Hashimoto M, Kikuchi S, Kuroda S, Yoshida R, Umeda Y, Urata Y, Kagawa S, Fujiwara T (2022) Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. Mol Ther Oncolytics 27:3\u201313. https:\/\/doi.org\/10.1016\/j.omto.2022.09.003","journal-title":"Mol Ther Oncolytics"},{"key":"5742_CR80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41417-025-00989-3","volume":"33","author":"T Nishiyama","year":"2026","unstructured":"Nishiyama T, Tazawa H, Nagai Y, Shoji R, Kajiwara Y, Hashimoto N, Takahashi Y, Kikuchi S, Kuroda S, Ohara T, Noma K, Yoshida R, Umeda Y, Tanaka HY, Kano MR, Masamune A, Urata Y, Kagawa S, Fujiwara T (2026) p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis. Cancer Gene Ther 33:223\u2013235. https:\/\/doi.org\/10.1038\/s41417-025-00989-3","journal-title":"Cancer Gene Ther"},{"key":"5742_CR81","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.21873\/anticanres.16678","volume":"43","author":"N Hori","year":"2023","unstructured":"Hori N, Tazawa H, Li Y, Okura T, Kikuchi S, Kuroda S, Ohara T, Noma K, Nishizaki M, Urata Y, Kagawa S, Fujiwara T (2023) Intraperitoneal administration of p53-armed oncolytic adenovirus inhibits peritoneal metastasis of diffuse-type gastric cancer cells. Anticancer Res 43:4809\u20134821. https:\/\/doi.org\/10.21873\/anticanres.16678","journal-title":"Anticancer Res"},{"key":"5742_CR82","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/mt.2016.135","volume":"24","author":"KF Pirollo","year":"2016","unstructured":"Pirollo KF, Nemunaitis J, Leung PK, Nunan R, Adams J, Chang EH (2016) Safety and efficacy in advanced solid tumors of a targeted nanocomplex carrying the p53 gene used in combination with docetaxel: a phase 1b study. Mol Ther 24:1697\u20131706. https:\/\/doi.org\/10.1038\/mt.2016.135","journal-title":"Mol Ther"},{"key":"5742_CR83","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1038\/s41388-018-0652-y","volume":"38","author":"I Ubby","year":"2019","unstructured":"Ubby I, Krueger C, Rosato R, Qian W, Chang J, Sabapathy K (2019) Cancer therapeutic targeting using mutant-p53-specific siRNAs. Oncogene 38:3415\u20133427. https:\/\/doi.org\/10.1038\/s41388-018-0652-y","journal-title":"Oncogene"},{"key":"5742_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051498","author":"J Yang Zhou","year":"2020","unstructured":"Yang Zhou J, Suwan K, Hajitou A (2020) Initial steps for the development of a phage-mediated gene replacement therapy using CRISPR-Cas9 technology. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9051498","journal-title":"J Clin Med"},{"key":"5742_CR85","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","volume":"53","author":"ML Leibowitz","year":"2021","unstructured":"Leibowitz ML, Papathanasiou S, Doerfler PA, Blaine LJ, Sun L, Yao Y, Zhang CZ, Weiss MJ, Pellman D (2021) Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. Nat Genet 53:895\u2013905. https:\/\/doi.org\/10.1038\/s41588-021-00838-7","journal-title":"Nat Genet"},{"key":"5742_CR86","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/01.ju.0000143196.37008.2c","volume":"173","author":"I Fodor","year":"2005","unstructured":"Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M (2005) Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 173:604\u2013609. https:\/\/doi.org\/10.1097\/01.ju.0000143196.37008.2c","journal-title":"J Urol"},{"key":"5742_CR87","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1158\/2767-9764.CRC-23-0394","volume":"3","author":"FJ Kos","year":"2023","unstructured":"Kos FJ, Frankel P, Cristea M, Eng M, Tinsley R, Dempsey S, Ruel N, Stewart D, Dellinger TH, Diamond DJ (2023) Immunologic signatures of peripheral blood T cells reveal the outcome of p53MVA vaccine and pembrolizumab treatment in patients with advanced ovarian cancer. Cancer Res Commun 3:2585\u20132595. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0394","journal-title":"Cancer Res Commun"},{"key":"5742_CR88","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2174\/1389450119666180115165447","volume":"19","author":"JFA Valente","year":"2018","unstructured":"Valente JFA, Queiroz JA, Sousa F (2018) p53 as the focus of gene therapy: past, present and future. Curr Drug Targets 19:1801\u20131817. https:\/\/doi.org\/10.2174\/1389450119666180115165447","journal-title":"Curr Drug Targets"},{"key":"5742_CR89","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41418-022-01007-x","volume":"29","author":"Y Yang","year":"2022","unstructured":"Yang Y, Yuan H, Zhao L, Guo S, Hu S, Tian M, Nie Y, Yu J, Zhou C, Niu J, Wang G, Song Y (2022) Targeting the miR-34a\/LRPPRC\/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer. Cell Death Differ 29:2177\u20132189. https:\/\/doi.org\/10.1038\/s41418-022-01007-x","journal-title":"Cell Death Differ"},{"key":"5742_CR90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41434-019-0071-x","volume":"27","author":"RE Tamura","year":"2020","unstructured":"Tamura RE, Lana MG, Costanzi-Strauss E, Strauss BE (2020) Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth. Gene Ther 27:15\u201326. https:\/\/doi.org\/10.1038\/s41434-019-0071-x","journal-title":"Gene Ther"},{"key":"5742_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133399","author":"J Krishnaraj","year":"2023","unstructured":"Krishnaraj J, Yamamoto T, Ohki R (2023) p53-dependent cytoprotective mechanisms behind resistance to chemo-radiotherapeutic agents used in cancer treatment. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15133399","journal-title":"Cancers (Basel)"},{"key":"5742_CR92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2415869122","volume":"122","author":"M Cao","year":"2025","unstructured":"Cao M, Gan Y, Huang Y, Tong J, Xiong C, Chen Y, Chen B, Huang R, Xie B, Deng J, Huang S, He X, Hao Q, Zhou X (2025) P53 activates circASCC3 to repress R-loops and enhance resistance to chemotherapy. Proc Natl Acad Sci U S A 122:e2415869122. https:\/\/doi.org\/10.1073\/pnas.2415869122","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5742_CR93","doi-asserted-by":"publisher","first-page":"17464","DOI":"10.1038\/s41598-020-74660-2","volume":"10","author":"N Kunimura","year":"2020","unstructured":"Kunimura N, Kitagawa K, Sako R, Narikiyo K, Tominaga S, Bautista DS, Xu W, Fujisawa M, Shirakawa T (2020) Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models. Sci Rep 10:17464. https:\/\/doi.org\/10.1038\/s41598-020-74660-2","journal-title":"Sci Rep"},{"key":"5742_CR94","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.3892\/mmr.2018.8408","volume":"17","author":"HB Qiao","year":"2018","unstructured":"Qiao HB, Li J, Lv LJ, Nie BJ, Lu P, Xue F, Zhang ZM (2018) The effects of interleukin 2 and rAd-p53 as a treatment for glioblastoma. Mol Med Rep 17:4853\u20134859. https:\/\/doi.org\/10.3892\/mmr.2018.8408","journal-title":"Mol Med Rep"},{"issue":"1","key":"5742_CR95","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41467-022-28279-8","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, Jiang X, Matsui A, Zhu L, Amoozgar Z, Chen DS, Han X, Duda DG, Shi J (2022) Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat Commun 13:758. https:\/\/doi.org\/10.1038\/s41467-022-28279-8","journal-title":"Nat Commun"},{"key":"5742_CR96","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41419-024-06783-7","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo Y, Wu H, Wiesmuller L, Chen M (2024) Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance. Cell Death Dis 15:412. https:\/\/doi.org\/10.1038\/s41419-024-06783-7","journal-title":"Cell Death Dis"},{"key":"5742_CR97","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12915-025-02214-x","volume":"23","author":"C Qin","year":"2025","unstructured":"Qin C, Wang YL, Zheng J, Wan XB, Fan XJ (2025) Current perspectives in drug targeting intrinsically disordered proteins and biomolecular condensates. BMC Biol 23:118. https:\/\/doi.org\/10.1186\/s12915-025-02214-x","journal-title":"BMC Biol"},{"key":"5742_CR98","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jmb.2008.09.019","volume":"384","author":"SG Sivakolundu","year":"2008","unstructured":"Sivakolundu SG, Nourse A, Moshiach S, Bothner B, Ashley C, Satumba J, Lahti J, Kriwacki RW (2008) Intrinsically unstructured domains of Arf and Hdm2 form bimolecular oligomeric structures in vitro and in vivo. J Mol Biol 384:240\u2013254. https:\/\/doi.org\/10.1016\/j.jmb.2008.09.019","journal-title":"J Mol Biol"},{"key":"5742_CR99","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1158\/0008-5472.CAN-26-2014","volume":"86","author":"E Destefanis","year":"2026","unstructured":"Destefanis E, Mulvaney KM (2026) ARF beyond p53: shaping the pancreatic tumor microenvironment. Cancer Res 86:3101\u20133102. https:\/\/doi.org\/10.1158\/0008-5472.CAN-26-2014","journal-title":"Cancer Res"},{"key":"5742_CR100","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1158\/0008-5472.CAN-25-1969","volume":"86","author":"S Ferreira","year":"2026","unstructured":"Ferreira S, Flowers BM, Choi WY, Farina-Morillas M, Gatto A, Bhattacharyya S, Boross G, Hassan G, Mulligan AS, Vogel H, Wood LD, Weaver VM, Winslow MM, Petrov DA, Sherman MH, Choi HY, Hayes DN, Aguirre AJ, Seoane JA, Attardi LD (2026) Inactivation of CDKN2AARF promotes p53-independent remodeling of the PDAC tumor microenvironment. Cancer Res 86:3109\u20133122. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-1969","journal-title":"Cancer Res"},{"key":"5742_CR101","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1089\/dna.2022.0115","volume":"42","author":"SA Mendonca","year":"2023","unstructured":"Mendonca SA, Antunes F, Cerqueira OLD, Del Valle PR, Hunger A, Oliveira PVS, Brito B, Costanzi-Strauss E, Strauss BE (2023) Induction of immune-stimulating factors and oncolysis upon p14(ARF) gene transfer in melanoma cell lines. DNA Cell Biol 42:274\u2013288. https:\/\/doi.org\/10.1089\/dna.2022.0115","journal-title":"DNA Cell Biol"},{"key":"5742_CR102","doi-asserted-by":"publisher","first-page":"576658","DOI":"10.3389\/fimmu.2020.576658","volume":"11","author":"OLD Cerqueira","year":"2020","unstructured":"Cerqueira OLD, Clavijo-Salomon MA, Cardoso EC, Citrangulo Tortelli Junior T, Mendonca SA, Barbuto JAM, Strauss BE (2020) Combined p14ARF and Interferon-beta Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation. Front Immunol 11:576658. https:\/\/doi.org\/10.3389\/fimmu.2020.576658","journal-title":"Front Immunol"},{"key":"5742_CR103","doi-asserted-by":"publisher","first-page":"1835389","DOI":"10.3389\/fimmu.2026.1835389","volume":"17","author":"OA Rodrigues","year":"2026","unstructured":"Rodrigues OA, Antunes F, Silva GRO, Niitsuma BN, da Luz J, Strauss BE (2026) Adenovirus mediated gene therapy in cell lines derived from canine oral melanoma. Front Immunol 17:1835389. https:\/\/doi.org\/10.3389\/fimmu.2026.1835389","journal-title":"Front Immunol"},{"key":"5742_CR104","first-page":"3646","volume":"63","author":"Y Huang","year":"2003","unstructured":"Huang Y, Tyler T, Saadatmandi N, Lee C, Borgstrom P, Gjerset RA (2003) Enhanced tumor suppression by a p14ARF\/p53 bicistronic adenovirus through increased p53 protein translation and stability. Cancer Res 63:3646\u20133653","journal-title":"Cancer Res"},{"key":"5742_CR105","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00432-020-03157-2","volume":"146","author":"T Muhammad","year":"2020","unstructured":"Muhammad T, Sakhawat A, Khan AA, Huang H, Khan HR, Huang Y, Wang J (2020) Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer. J Cancer Res Clin Oncol 146:861\u2013874. https:\/\/doi.org\/10.1007\/s00432-020-03157-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"5742_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020258","author":"RL Fine","year":"2023","unstructured":"Fine RL, Mao Y, Garcia-Carracedo D, Su GH, Qiu W, Hochfeld U, Nichols G, Li YL, Dinnen RD, Raffo A, Brandt-Rauf PW (2023) Gene therapy with p14\/tBID induces selective and synergistic apoptosis in mutant Ras and mutant p53 cancer cells in vitro and in vivo. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11020258","journal-title":"Biomedicines"},{"key":"5742_CR107","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/0008-5472.CAN-18-1753","volume":"79","author":"P Vummidi Giridhar","year":"2019","unstructured":"Vummidi Giridhar P, Williams K, VonHandorf AP, Deford PL, Kasper S (2019) Constant degradation of the androgen receptor by MDM2 conserves prostate cancer stem cell integrity. Cancer Res 79:1124\u20131137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1753","journal-title":"Cancer Res"},{"key":"5742_CR108","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3389\/fphar.2020.00631","volume":"11","author":"W Li","year":"2020","unstructured":"Li W, Peng X, Lang J, Xu C (2020) Targeting mouse double minute 2: current concepts in DNA damage repair and therapeutic approaches in cancer. Front Pharmacol 11:631. https:\/\/doi.org\/10.3389\/fphar.2020.00631","journal-title":"Front Pharmacol"},{"key":"5742_CR109","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12935-019-0937-4","volume":"19","author":"H Hou","year":"2019","unstructured":"Hou H, Sun D, Zhang X (2019) The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int 19:216. https:\/\/doi.org\/10.1186\/s12935-019-0937-4","journal-title":"Cancer Cell Int"},{"key":"5742_CR110","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1309\/AJCPLYU89XHSNHQO","volume":"141","author":"PL Ware","year":"2014","unstructured":"Ware PL, Snow AN, Gvalani M, Pettenati MJ, Qasem SA (2014) MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors. Am J Clin Pathol 141:334\u2013341. https:\/\/doi.org\/10.1309\/AJCPLYU89XHSNHQO","journal-title":"Am J Clin Pathol"},{"key":"5742_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413516","author":"FCC de Faria","year":"2024","unstructured":"de Faria FCC, Khurshid S, Sarchet P, Tahara S, Casadei L, Grignol V, Karna R, Rentsch S, Sp N, Beane JD, Mazzoccoli L, Montes M, Nigita G, Sharick JT, Leight JL, Calore F, Chandler DS, Pollock RE (2024) Oncogenic functions of alternatively spliced MDM2-ALT2 isoform in retroperitoneal liposarcoma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252413516","journal-title":"Int J Mol Sci"},{"key":"5742_CR112","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.ejca.2013.12.027","volume":"50","author":"J Gu","year":"2014","unstructured":"Gu J, Wang B, Liu Y, Zhong L, Tang Y, Guo H, Jiang T, Wang L, Li Y, Cai L (2014) Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. Eur J Cancer 50:1184\u20131194. https:\/\/doi.org\/10.1016\/j.ejca.2013.12.027","journal-title":"Eur J Cancer"},{"key":"5742_CR113","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102420118","author":"AM Klein","year":"2021","unstructured":"Klein AM, Biderman L, Tong D, Alaghebandan B, Plumber SA, Mueller HS, van Vlimmeren A, Katz C, Prives C (2021) MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2102420118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5742_CR114","doi-asserted-by":"publisher","first-page":"444","DOI":"10.21873\/cgp.20512","volume":"22","author":"DH Shen","year":"2025","unstructured":"Shen DH, Chan HP, Tsai FR, Chiu YL, Liang TJ, She Y, Liu AC, Yeh HY, Tsai KW, Li SC (2025) MDM2 knockdown reduces the oncogenic activities and enhances NIS protein abundance in papillary thyroid cancer. Cancer Genomics Proteom 22:444\u2013457. https:\/\/doi.org\/10.21873\/cgp.20512","journal-title":"Cancer Genomics Proteom"},{"key":"5742_CR115","doi-asserted-by":"publisher","first-page":"44013","DOI":"10.18632\/oncotarget.9768","volume":"7","author":"Q Huang","year":"2016","unstructured":"Huang Q, Li L, Li L, Chen H, Dang Y, Zhang J, Shao N, Chang H, Zhou Z, Liu C, He B, Wei H, Xiao J (2016) MDM2 knockdown mediated by a triazine-modified dendrimer in the treatment of non-small cell lung cancer. Oncotarget 7:44013\u201344022. https:\/\/doi.org\/10.18632\/oncotarget.9768","journal-title":"Oncotarget"},{"key":"5742_CR116","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G (2021) Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther 6:53. https:\/\/doi.org\/10.1038\/s41392-021-00487-6","journal-title":"Signal Transduct Target Ther"},{"key":"5742_CR117","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.hoc.2022.05.001","volume":"36","author":"HL Malech","year":"2022","unstructured":"Malech HL, Garabedian EK, Hsieh MM (2022) Evolution of gene therapy, historical perspective. Hematol Oncol Clin North Am 36:627\u2013645. https:\/\/doi.org\/10.1016\/j.hoc.2022.05.001","journal-title":"Hematol Oncol Clin North Am"},{"key":"5742_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/v15030698","author":"K Lundstrom","year":"2023","unstructured":"Lundstrom K (2023) Viral vectors in gene therapy: where do we stand in 2023? Viruses. https:\/\/doi.org\/10.3390\/v15030698","journal-title":"Viruses"},{"key":"5742_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109235","volume":"183","author":"S Glaschke","year":"2024","unstructured":"Glaschke S, Dobrovolny HM (2024) Spatiotemporal spread of oncolytic virus in a heterogeneous cell population. Comput Biol Med 183:109235. https:\/\/doi.org\/10.1016\/j.compbiomed.2024.109235","journal-title":"Comput Biol Med"},{"key":"5742_CR120","doi-asserted-by":"publisher","first-page":"101345","DOI":"10.1016\/j.drup.2025.101345","volume":"85","author":"X Wang","year":"2026","unstructured":"Wang X, Fan R, Wang G, Han B, Zhou L, Tong A, Zou B, Guo G (2026) Overcoming resistance in oncolytic virotherapy: nano-engineered solutions for systemic delivery and efficacy boost. Drug Resist Updat 85:101345. https:\/\/doi.org\/10.1016\/j.drup.2025.101345","journal-title":"Drug Resist Updat"},{"key":"5742_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201073","volume":"33","author":"MA Russo-Maenza","year":"2025","unstructured":"Russo-Maenza MA, Rios GD, Hirschson Alvarez Prado LM, Sanchez Lamas MS, Vinueza Sarango GA, Sanchez DS, Derrer CP, Afonso J, Bravo AI, Rotondaro C, Coraglio M, Sendoya JM, Llera AS, Podhajcer OL, Cafferata EGA (2025) Tackling cancer heterogeneity with systemically delivered oncolytic adenoviruses transcriptionally targeted with hybrid promoters. Mol Ther Oncolytics 33:201073. https:\/\/doi.org\/10.1016\/j.omton.2025.201073","journal-title":"Mol Ther Oncolytics"},{"key":"5742_CR122","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00262-016-1807-8","volume":"65","author":"RF Medrano","year":"2016","unstructured":"Medrano RF, Catani JP, Ribeiro AH, Tomaz SL, Merkel CA, Costanzi-Strauss E, Strauss BE (2016) Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy. Cancer Immunol Immunother 65:371\u2013382. https:\/\/doi.org\/10.1007\/s00262-016-1807-8","journal-title":"Cancer Immunol Immunother"},{"key":"5742_CR123","doi-asserted-by":"publisher","first-page":"17017","DOI":"10.1038\/cddiscovery.2017.17","volume":"3","author":"A Hunger","year":"2017","unstructured":"Hunger A, Medrano RF, Zanatta DB, Del Valle PR, Merkel CA, Salles TA, Ferrari DG, Furuya TK, Bustos SO, de Freitas Saito R, Costanzi-Strauss E, Strauss BE (2017) Reestablishment of p53\/Arf and interferon-beta pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death. Cell Death Discov 3:17017. https:\/\/doi.org\/10.1038\/cddiscovery.2017.17","journal-title":"Cell Death Discov"},{"key":"5742_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.762796","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, Fan C, Zeng Z, Young KH, Li Y (2021) Clinical and immunological effects of p53-targeting vaccines. Front Cell Dev Biol 9:762796. https:\/\/doi.org\/10.3389\/fcell.2021.762796","journal-title":"Front Cell Dev Biol"},{"key":"5742_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216766","volume":"588","author":"S Chauhan","year":"2024","unstructured":"Chauhan S, Jaiswal S, Jakhmola V, Singh B, Bhattacharya S, Garg M, Sengupta S (2024) Potential role of p53 deregulation in modulating immune responses in human malignancies: a paradigm to develop immunotherapy. Cancer Lett 588:216766. https:\/\/doi.org\/10.1016\/j.canlet.2024.216766","journal-title":"Cancer Lett"},{"key":"5742_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005068","author":"Z Yang","year":"2022","unstructured":"Yang Z, Sun JK, Lee MM, Chan MK (2022) Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005068","journal-title":"J Immunother Cancer"},{"key":"5742_CR127","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41571-023-00842-2","volume":"21","author":"A Tuval","year":"2024","unstructured":"Tuval A, Strandgren C, Heldin A, Palomar-Siles M, Wiman KG (2024) Pharmacological reactivation of p53 in the era of precision anticancer medicine. Nat Rev Clin Oncol 21:106\u2013120. https:\/\/doi.org\/10.1038\/s41571-023-00842-2","journal-title":"Nat Rev Clin Oncol"},{"key":"5742_CR128","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s11418-025-01906-6","volume":"79","author":"S Tsukamoto","year":"2025","unstructured":"Tsukamoto S (2025) Natural products that target p53 for cancer therapy. J Nat Med 79:725\u2013737. https:\/\/doi.org\/10.1007\/s11418-025-01906-6","journal-title":"J Nat Med"},{"key":"5742_CR129","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","volume":"49","author":"S Shangary","year":"2009","unstructured":"Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223\u2013241. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094723","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"5742_CR130","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M (2023) Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov 22:127\u2013144. https:\/\/doi.org\/10.1038\/s41573-022-00571-8","journal-title":"Nat Rev Drug Discov"},{"key":"5742_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1444437","volume":"15","author":"Z Song","year":"2024","unstructured":"Song Z, Tao Y, Liu Y, Li J (2024) Advances in delivery systems for CRISPR\/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles. Front Immunol 15:1444437. https:\/\/doi.org\/10.3389\/fimmu.2024.1444437","journal-title":"Front Immunol"},{"key":"5742_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/v16071094","author":"M Salauddin","year":"2024","unstructured":"Salauddin M, Saha S, Hossain MG, Okuda K, Shimada M (2024) Clinical application of adenovirus (AdV): a comprehensive review. Viruses. https:\/\/doi.org\/10.3390\/v16071094","journal-title":"Viruses"},{"key":"5742_CR133","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jconrel.2020.09.003","volume":"327","author":"P Boucher","year":"2020","unstructured":"Boucher P, Cui X, Curiel DT (2020) Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors. J Control Release 327:788\u2013800. https:\/\/doi.org\/10.1016\/j.jconrel.2020.09.003","journal-title":"J Control Release"},{"key":"5742_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/biology13121052","author":"A Muravyeva","year":"2024","unstructured":"Muravyeva A, Smirnikhina S (2024) Adenoviral vectors for gene therapy of hereditary diseases. Biology. https:\/\/doi.org\/10.3390\/biology13121052","journal-title":"Biology"},{"key":"5742_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052417","author":"F Kreppel","year":"2021","unstructured":"Kreppel F, Hagedorn C (2021) Capsid and genome modification strategies to reduce the immunogenicity of adenoviral vectors. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22052417","journal-title":"Int J Mol Sci"},{"key":"5742_CR136","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","volume":"9","author":"M Schmid","year":"2018","unstructured":"Schmid M, Ernst P, Honegger A, Suomalainen M, Zimmermann M, Braun L, Stauffer S, Thom C, Dreier B, Eibauer M, Kipar A, Vogel V, Greber UF, Medalia O, Pluckthun A (2018) Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Commun 9:450. https:\/\/doi.org\/10.1038\/s41467-017-02707-6","journal-title":"Nat Commun"},{"key":"5742_CR137","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1093\/nar\/23.14.2584","volume":"23","author":"A Zauberman","year":"1995","unstructured":"Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M (1995) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23:2584\u201392. https:\/\/doi.org\/10.1093\/nar\/23.14.2584","journal-title":"Nucleic Acids Res"},{"key":"5742_CR138","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.bjc.6604643","volume":"99","author":"M Dimitriadi","year":"2008","unstructured":"Dimitriadi M, Poulogiannis G, Liu L, Backlund LM, Pearson DM, Ichimura K, Collins VP (2008) P53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours. Br J Cancer 99:1144\u201352. https:\/\/doi.org\/10.1038\/sj.bjc.6604643","journal-title":"Br J Cancer"},{"key":"5742_CR139","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.virol.2003.12.021","volume":"321","author":"BE Strauss","year":"2004","unstructured":"Strauss BE, Costanzi-Strauss E (2004) pCLPG: a p53-driven retroviral system. Virology 321:165\u2013172. https:\/\/doi.org\/10.1016\/j.virol.2003.12.021","journal-title":"Virology"},{"key":"5742_CR140","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.cgt.7700846","volume":"12","author":"BE Strauss","year":"2005","unstructured":"Strauss BE, Bajgelman MC, Costanzi-Strauss E (2005) A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition. Cancer Gene Ther 12:935\u2013946. https:\/\/doi.org\/10.1038\/sj.cgt.7700846","journal-title":"Cancer Gene Ther"},{"key":"5742_CR141","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.virol.2007.11.015","volume":"371","author":"MC Bajgelman","year":"2008","unstructured":"Bajgelman MC, Strauss BE (2008) Development of an adenoviral vector with robust expression driven by p53. Virology 371:8\u201313","journal-title":"Virology"},{"key":"5742_CR142","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12896-015-0121-4","volume":"15","author":"H Chen","year":"2015","unstructured":"Chen H, Wang D, Xia R, Mao Q, Xia H (2015) A novel adenoviral vector carrying an all-in-one Tet-On system with an autoregulatory loop for tight, inducible transgene expression. BMC Biotechnol 15:4. https:\/\/doi.org\/10.1186\/s12896-015-0121-4","journal-title":"BMC Biotechnol"},{"key":"5742_CR143","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1475-2867-5-27","volume":"5","author":"TY Chi","year":"2005","unstructured":"Chi TY, Chen GG, Ho LK, Lai PB (2005) Establishment of a doxycycline-regulated cell line with inducible, doubly-stable expression of the wild-type p53 gene from p53-deleted hepatocellular carcinoma cells. Cancer Cell Int 5:27. https:\/\/doi.org\/10.1186\/1475-2867-5-27","journal-title":"Cancer Cell Int"},{"key":"5742_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031737","author":"ES Omelina","year":"2022","unstructured":"Omelina ES, Yushkova AA, Motorina DM, Volegov GA, Kozhevnikova EN, Pindyurin AV (2022) Optogenetic and chemical induction systems for regulation of transgene expression in plants: use in basic and applied research. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23031737","journal-title":"Int J Mol Sci"},{"key":"5742_CR145","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3332\/ecancer.2017.751","volume":"11","author":"B Javan","year":"2017","unstructured":"Javan B, Shahbazi M (2017) Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy. Ecancermedicalscience 11:751. https:\/\/doi.org\/10.3332\/ecancer.2017.751","journal-title":"Ecancermedicalscience"},{"key":"5742_CR146","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/elsc.202100045","volume":"21","author":"CKC Lam","year":"2021","unstructured":"Lam CKC, Truong K (2021) Design of a synthesis-friendly hypoxia-responsive promoter for cell-based therapeutics. Eng Life Sci 21:848\u2013856. https:\/\/doi.org\/10.1002\/elsc.202100045","journal-title":"Eng Life Sci"},{"key":"5742_CR147","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41418-023-01253-7","volume":"31","author":"LD Attardi","year":"2024","unstructured":"Attardi LD, Boutelle AM (2024) Targeting p53 gain-of-function activity in cancer therapy: a cautionary tale. Cell Death Differ 31:133\u2013135. https:\/\/doi.org\/10.1038\/s41418-023-01253-7","journal-title":"Cell Death Differ"},{"key":"5742_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02891-1","volume":"12","author":"L Bartolomei","year":"2025","unstructured":"Bartolomei L, Ciribilli Y, Brugnara S, Reggiani F, Moretta GM, Petito M, Marcaccini E, Ambrosio M, Mosci C, Pfeffer U, Amaro A, Monti P, Bisio A (2025) Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma. Cell Death Discov 12:39. https:\/\/doi.org\/10.1038\/s41420-025-02891-1","journal-title":"Cell Death Discov"},{"key":"5742_CR149","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1038\/sj.onc.1210294","volume":"26","author":"L Weisz","year":"2007","unstructured":"Weisz L, Oren M, Rotter V (2007) Transcription regulation by mutant p53. Oncogene 26:2202\u20132211. https:\/\/doi.org\/10.1038\/sj.onc.1210294","journal-title":"Oncogene"},{"key":"5742_CR150","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/jmcb\/mjy072","volume":"11","author":"X Zhou","year":"2019","unstructured":"Zhou X, Hao Q, Lu H (2019) Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol 11:293\u2013305. https:\/\/doi.org\/10.1093\/jmcb\/mjy072","journal-title":"J Mol Cell Biol"},{"key":"5742_CR151","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2024.5448","author":"ML Tornesello","year":"2025","unstructured":"Tornesello ML (2025) TP53 mutations in cancer: molecular features and therapeutic opportunities (review). Int J Mol Med. https:\/\/doi.org\/10.3892\/ijmm.2024.5448","journal-title":"Int J Mol Med"},{"key":"5742_CR152","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","volume":"24","author":"S Peuget","year":"2024","unstructured":"Peuget S, Zhou X, Selivanova G (2024) Translating p53-based therapies for cancer into the clinic. Nat Rev Cancer 24:192\u2013215. https:\/\/doi.org\/10.1038\/s41568-023-00658-3","journal-title":"Nat Rev Cancer"},{"key":"5742_CR153","doi-asserted-by":"publisher","unstructured":"Russano F, Sturlese M, Dall\u2019Olmo L, Callegarin F, Brugnolo D, Del Fiore P, Patti V, Purpura A, Moro S, Rastrelli M, Mocellin S (2025) MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials. Int J Mol Sci\u00a0https:\/\/doi.org\/10.3390\/ijms27010099","DOI":"10.3390\/ijms27010099"},{"key":"5742_CR154","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1101\/gad.353408.125","volume":"40","author":"G Efe","year":"2026","unstructured":"Efe G, Cunningham K, Rustgi AK, Prives C, Manfredi JJ, Sanchez-Rivera FJ (2026) Mutant p53: evolving perspectives. Genes Dev 40:4\u201325. https:\/\/doi.org\/10.1101\/gad.353408.125","journal-title":"Genes Dev"},{"key":"5742_CR155","doi-asserted-by":"publisher","first-page":"179","DOI":"10.22099\/mbrc.2025.51477.2054","volume":"14","author":"R Mirgayazova","year":"2025","unstructured":"Mirgayazova R, Khadiullina R, Gilyazova E, Davletshin D, Ganeeva I, Zmievskaya E, Chasov V, Valiullina A, Bulatov E (2025) The importance of TP53 status in cancer therapy: the example of chronic lymphocytic leukemia. Mol Biol Res Commun 14:179\u2013198. https:\/\/doi.org\/10.22099\/mbrc.2025.51477.2054","journal-title":"Mol Biol Res Commun"},{"key":"5742_CR156","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1200\/OP.24.00226","volume":"20","author":"AK Dowdell","year":"2024","unstructured":"Dowdell AK, Meng RC, Vita A, Bapat B, Hanes D, Chang SC, Harold L, Wong C, Poon H, Schroeder B, Weerasinghe R, Leidner R, Urba WJ, Bifulco CB, Piening BD (2024) Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health system. JCO Oncol Pract 20:1523\u20131532. https:\/\/doi.org\/10.1200\/OP.24.00226","journal-title":"JCO Oncol Pract"},{"key":"5742_CR157","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/atm-25-34","volume":"13","author":"M Jamalinia","year":"2025","unstructured":"Jamalinia M, Weiskirchen R (2025) Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment. Ann Transl Med 13:18. https:\/\/doi.org\/10.21037\/atm-25-34","journal-title":"Ann Transl Med"},{"key":"5742_CR158","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7150\/jca.123742","volume":"17","author":"J Hu","year":"2026","unstructured":"Hu J, Zhou W, Zhao Y, Li P, Zhao Z, Wang W, Wang W, Wang Y (2026) Cancer cell dormancy and chemotherapy resistance. J Cancer 17:59\u201373. https:\/\/doi.org\/10.7150\/jca.123742","journal-title":"J Cancer"},{"key":"5742_CR159","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1200\/JCO.21.02285","volume":"40","author":"BP Hobbs","year":"2022","unstructured":"Hobbs BP, Pestana RC, Zabor EC, Kaizer AM, Hong DS (2022) Basket Trials: Review of Current Practice and Innovations for Future Trials. J Clin Oncol 40:3520\u20133528. https:\/\/doi.org\/10.1200\/JCO.21.02285","journal-title":"J Clin Oncol"},{"key":"5742_CR160","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","volume":"375","author":"DL Bhatt","year":"2016","unstructured":"Bhatt DL, Mehta C (2016) Adaptive designs for clinical trials. N Engl J Med 375:65\u201374. https:\/\/doi.org\/10.1056\/NEJMra1510061","journal-title":"N Engl J Med"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05742-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05742-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05742-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:29Z","timestamp":1792569329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05742-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":160,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5742"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05742-4","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BES is an Associate Editor of Molecular and Cellular Biochemistry. However, the authors have no financial conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}